Economic costs to business of the HIV/AIDS epidemic

PharmacoEconomics

Volumn 22, Issue 18, 2004, Pages 1181-1194

  Liu, Gordon G ^a,b,c   Guo, Jeff J ^c   Smith, Scott R ^a,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b PEKING UNIVERSITY   (China)

^c UNIVERSITY OF CINCINNATI   (United States)

^d AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIBLIOGRAPHIC DATABASE; EMPLOYMENT; EPIDEMIC; HEALTH CARE COST; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; UNITED STATES; WORKMAN COMPENSATION;

COMMERCE; COST OF ILLNESS; DATABASES, FACTUAL; DISEASE OUTBREAKS; EMPLOYER HEALTH COSTS; HIV INFECTIONS; HUMANS;

EID: 11344256446     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422180-00003     Document Type: Review

References (71)

1. United Nations Program for AIDS (UNAIDS). Fighting AIDS: a new global resolve. In: report on the global HIV/AIDS epidemic 2002; 8-20 [online]. Available from URL: http:// www.unaids.org [Accessed 2003 Aug 1]
2. Bloom DE, Rosenfield A. A moment in time: AIDS and business. AIDS Patient Care STDS 2000; 14 (9): 509-17
3. United Nations Program for AIDS (UNAIDS). Report on the Global HIV/AIDS Epidemic 2000
4. Harmonie Toros, U.N. warns of HIV/AIDS spread. Associated Press News, USA Today, July 2,2002 [online]. Available from URL: http://www.usatoday.com [Accessed 2003 Aug 1]
5. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135 (1): 17-26
6. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352 (9142): 1725-30
7. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 228 (13): 853-60
8. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179 (3): 717-20
9. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288: 222-35
10. US Department of Health and Human Services, US Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Bethesda (MD): Dept of Health and Human Services and the Henry Institutes of Health, 2001 Aug 13
11. Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53: 2004; 558-61
12. Hay JW, Osmond DH, Jacobson MA. Projecting the medical costs of AIDS and ARC in the United States. J AIDS 1998; 1: 466-85
13. Hellinger FJ. Forecasting the medical care costs of the HIV epidemic: 1991-1994. Inquiry 1991; 28: 356-65
14. Scitovsky AA, Rice D. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987; 102(1): 5-17
15. Hanvelt RA, Ruedy NS, Hogg RS, et al. Indirect costs of HIV/ AIDS mortality in Canada. AIDS 1994; 8: F7-11
16. Scitovsky AA, Cline MW, Abrams DI. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months. J Acquir Immune Defic Syndr 1990; 3: 904-12
17. Seage III GR, Landers S, Lamb GA, et al. Effects of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS). Am J Public Health 1990; 80: 835-9
18. Andrulis DP, Weslowski VB, Hintz E, et al. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA 1992; 267: 2482-6
19. Bozzette SA, Bery SH, Duan N, et al. The care of HIV-infected adults in the United States. N Engl J Med 1998; 339: 1897-904
20. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817-23
21. Mullins CD, Whitelaw G, Cooke JL, et al. Indirect cost of HIV infection in England. Clin Ther 2000; 22 (11): 1333-45
22. World Health Organization (WHO) and International Labor Organization (ILO). Consultation sur le sida et le lieu de travail: declaration de Geneve, Geneve, 1988 Jun 27-29
23. Farnham PG. Defining and measuring the costs of the HIV epidemic to businesses. Public Health Rep 1994; 109 (3): 311-8
24. Farnham G, Gorsky R. Costs to business for an HIV-infected worker. Inquiry 1994; 31: 76-88
25. Bloom DE, Glied S. Benefits and costs of HIV testing. Science 1991 Jun 28; 252: 1798-804
26. Whiteside A, Sunter C. AIDS: the challenge for South Africa. Cape Town: Human & Rousseau and Tafelberg, 2000; 112
27. Liu GG, Yin DD, Lyu R, et al. Economic costs of HIV infection: an employer's perspective. Eur J Health Econ 2002; 3: 226-34
28. Gershy-Damet GM, Koffit K, Soro B, et al. Seroepidemiological survery of HIV-1 and HIV-2 infections in the five regions of Ivory Coast. AIDS 1991; 5 (4): 462-3
29. De Cock KM. Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. WHO AIDS Tech Bull 1989; 2: 157-8
30. Breuer NL. Learning from the global village: corporate responsibility around the world: clinical care options for HIV. Medscape HIV/AIDS. 1998; 4: 4 [online]. Available from URL: http://www.medscape.com/ [Accessed 2002 May]
31. Sebesta D, LaPlante M. HIV/AIDS, disability and employment. Disability statistics report (6). Washington, DC: National Institute on Disability and Rehabilitation Research, Department of Education, 1996
32. Pramualratana A. Thailand Business Coalition on AIDS: businesses must face AIDS in the workplace. HIV/AIDS action in developing countries. European Union AIDS Program in developing countries. 1999 Feb 3
33. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14 (3): 223-31
34. Hellinger FJ, Fleishman JA. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr 2000; 24 (2): 182-8
35. Cuddington JT. Further results on the macroeconomic effects of AIDS: the dualistic, labor-surplus economy. World Bank Econ Rev 1993; 7 (3): 403-17
36. Theodore K. HIV/AIDS in the Caribbean: economic issues: impact and investment response [online]. Available from URL: http://www.ilocarib.org.tt/ infsources/hiv_aids/theodore [Accessed 2002 Oct]
37. Hancock J, Nalo D, Aoko M, et al. The macroeconomic impact of HIV/AIDS. In: Forsythe S, Rau B, editors. AIDS in Kenya: socioeconomic impact and policy implications. Arlington (VA): Family Health International, 1996
38. Bollinger L, Stover J, Kerkhoven R, et al. The economic impact of AIDS in Zimbabwe. Washington, (DC): Futures Group International, 1999
39. Bollinger L, Stover J, Riwa P. The economic impact of AIDS in Tanzania. Washington (DC): The Futures Group International, 1999 Sept
40. Machlin S, Cohen J, Zuvekas S, et al. Per Capita health care expenses 1996. Rockville (MD): Agency for Health Care Research and Quality; 2000. Highlights No. 12. AHRQ Pub. No. 00-0026
41. Bureau of Labor Statistics (BLS). The CPI for medical care prices as fixed market basket of medical commodities and services. Compensation and Working Conditions, 1997; 3-11
42. Kane JJ, Blostin AP, Pfuntner JN. Changing survey strategies in the evolution of health care plans. Compensation and working conditions. Washington (DC): US Department of Labor, 1996; 3-10
43. Hyland S. Health benefits show cost containment strategies. Monthly Labor Review, US Department of Labor. Washington (DC): 1992 Feb; 42-3
44. Burke TP. Alternatives to hospital care under employee benefit plans. Monthly Labor Review. US Department of Labor. Washington (DC): 1991; 1997, 1998, 1999, 2000, 2001, 2002. US Department of Labor [online]. Available from URL: http:// www.bls.gov. [Accessed 2003 June]
45. Schwenk AE. Trends in health insurance costs: compensation and working condition [online]. The Bureau of Labor Statistics,
46. Spring 1999, 4 (1). Available from URL: http://www.bls. gov/opub/cwc/1999/spring/ [Accessed 2002 May]
47. Bollinger L, Stover J, Nalo D. The economic impact of AIDS in Kenya. Washington (DC): Futures Group International, 1999 Sep
48. Aventin L, Huard P. HIV/AIDS and manufacturing in Abidjan. AIDS Anal Afr 1997; 7 (3): 2-4
49. Sendi P, Palmer AJ, Gafni A, et al. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 2001; 19 (7): 709-13
50. Marseille E, Kahn JG, Saba J. The costs and benefits of employer-sponsored anti-retroviral drug provision [abstract]. 2000 July 11; Durban South Africa. XIII International AIDS Conference 2000, 22
51. Sendi PP, Bucher HC, Harr T, et al. Cost-effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS 1999; 13: 1115-22
52. International Labor Organization (ILO). A regional study of the impact of HIV/AIDS on the productive labor force, November 1999, Geneva [online]. Available from URL: http://ilo.org/ public/english/protection/trav/aids/ initiatives.htm [Accessed 2002 Aug 4]
53. Kwaramba P. The socioeconomic impact of HIV/AIDS on communal agricultural systems in Zimbabwe, Zimbabwe Farmers Union, Harare. UNAIDS 1997 [online]. Available from URL: http://www.un.org/esa/population/publications/ [Accessed 2002 May]
54. Bollinger L, Stover J, Martin-Correa LJ. The economic impact of AIDS in Benin. US Agency for International Development under contract No. CCP-C-00-95-00023-04. The Futures Group International, 1999 Sep; 1-12
55. Forsythe S, Roberts M, Wongombe J, et al. Measuring the impacts of HIV/AIDS on Africa's commercial sector [abstract]. Int Conf. AIDS 1994; 10: 13
56. Forsythe S, Wienrawee P. The socioeconomic impact of HIV/ AIDS in Thailand's workplace [abstract]; 2000 Jul;. Durban. South Africa. XIII International AIDS Conference 1996; 11: 246
57. McNeil DG. AIDS stalking Africa's struggling economies, New York Times, 1998 Nov 15
58. Over M. The macroeconomic impact of AIDS in sub-Saharan Africa. Technical Working Paper #3. Washington, (DC): World Bank, Africa Technical Department, Population, Health and Nutrition Division, 1992
59. Rugalema G. HIV/AIDS and the commercial agricultural sector of Kenya: impact, vulnerability, susceptibility and coping strategies. Sustainable Development Department. Food and Organization of the United Nations (FAO) 1999 Jul 3
60. Rau B, Roberts M, editors. Private sector AIDS policy: businesses managing HIV/AIDS. Arlington (VA): AIDSCAP/ Family Health International, 1996
61. Leigh JP, Lubeck DP, Fanham PG, et al. Hours at work and employment status among HIV-infected patients. AIDS 1995; 9: 81-88
62. Yelin EH, Greenlatt RM, Hollander H, et al. The impact of HIV-related illness on employment. Am J Public Health 1991; 81: 79-84
63. Biggs T, Shah M. The Impact of the AIDS epidemic on African firms. RPED Discussion Paper No. 72, Regional Program on Enterprise Development, The World Bank, 1997 Jan [online]. Available from URL: http://www.un.org/esa/population [Accessed 2002 May]
64. Rijckborst H. Heineken HIV/AIDS policy: the workplace response to AIDS. Heineken International Jan 2002 [online]. Available from URL: http://www.smartwork.org/resources/ [Accessed 2002 Oct]
65. Chibbaro L. DC sued for HIV discrimination: corporation counsel's office named in disabilities act suit. Washington Blade; 2001 Jul
66. UNAIDS: putting HIV/AIDS on the business agenda. UNAIDS point of view. Geneva; Nov 1998 [online]. Available from URL: http://worldbank.org/wbi/ [Accessed 2002 Oct]
67. Schneider P. Economics of HIV/AIDS in developing countries: economic impact of HIV/AIDS on South Africa. Presented at the International AIDS Economic Network (IAEN) symposium. Durban; South Africa, 2000 Jul
68. [Anonymous]. The worst way to lose talent. The Economist, 2001 Feb [online]. Available from URL: http:// www.cid.harvard.edu/ [Accessed 2002 May]
69. Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001 Jan; 19 (1): 13-39
70. Who is bearing the cost of the AIDS epidemic in Asia? In: Bloom D, Lyons J, editors. Economic implications of AIDS in Asia. New Delhi: United National Development Programme, 1993
71. Japsen B. Abbott to sell HIV drugs at cost in Africa: other countries may want cuts. Chicago Tribune. Business section. Page 1. 2001 Mar 28